Today: 29 June 2026
Browse Category

ASX:MVF 24 November 2025

Monash IVF (ASX: MVF) Share Price Soars as Board Rejects 80¢ Takeover Bid and Macquarie Sees 54% Upside

Monash IVF (ASX: MVF) Share Price Soars as Board Rejects 80¢ Takeover Bid and Macquarie Sees 54% Upside

Sydney – 24 November 2025 Monash IVF Group Ltd has surged back into the spotlight today after rejecting an 80¢-per-share takeover proposal from a private equity–backed consortium, sending the embattled fertility stock up around 40–41% to about 86¢ and putting it among the top performers on the ASX All Ordinaries Index. Reuters+1
24 November 2025
···
ASX 200 Today: Index Rebounds From Near Six‑Month Low as Banks, Miners Lift the Market – 24 November 2025

ASX 200 Today: Index Rebounds From Near Six‑Month Low as Banks, Miners Lift the Market – 24 November 2025

After one of its roughest weeks of 2025, the S&P/ASX 200 is trying to claw back lost ground on Monday, 24 November. By late morning in Sydney, the benchmark index was up around 1.1%, or roughly 90 points, trading near 8,507 as every major sector moved higher in early trade.Market Index+1 The bounce comes after a brutal Friday session where the ASX 200 slumped 1.6% to close at 8,416.5, wiping almost $40 billion from the market and marking a fourth straight weekly loss of around 2.5%.ABC+1 The index is still roughly 7–8% below its October record high of just over 9,100 points, meaning talk of a possible technical correction hasn’t gone away.ABC+1
24 November 2025
·····

Stock Market Today

  • Ford (F) Slips as Recalls Weigh on Stock, Quality Scores Up
    June 29, 2026, 5:54 PM EDT. Ford Motor Company shares slipped 0.7% to $14.02, lagging behind the S&P 500's 1.7% jump and a 2.4% rise in Consumer Discretionary stocks. The automaker's J.D. Power initial-quality score improved 21% to 152 problems per 100 vehicles, leading mass-market brands, but investors saw little lift with 51 recalls so far this year. The average analyst price target is at $14.78, around 5% above where the stock now trades, with most analysts stuck at Hold. The split reaction signals many doubt recent quality gains are enough to outweigh recall issues.
Go toTop